Special clinical challenges in autoimmune hepatitis: The elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients

Seminars in Liver Disease

Volumn 29, Issue 3, 2009, Pages 315-330

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Diagnostic difficulties; Treatment recommendations; Variant presentations

Indexed keywords

ALENDRONIC ACID; ANTIGEN; AZATHIOPRINE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MERCAPTOPURINE; PREDNISONE;

AGED; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DELIVERY; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; GENDER; HEPATITIS A; HEPATITIS B; HEREDITY; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; MALE; NONHUMAN; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SYMPTOM;

ADULT; AGE FACTORS; CONTINENTAL POPULATION GROUPS; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 68849087156     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0029-1233530     Document Type: Review

References (200)

1. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol 2005; 51(4):313-333
2. Czaja AJ, Freese DK; American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36(2):479-497
3. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5): 929-938
4. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified diagnostic criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-176
5. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008;48(5): 1540-1548
6. Crapper RM, Bhathal PS, Mackay IR, Frazer IH. 'Acute' autoimmune hepatitis. Digestion 1986;34(3):216-225
7. Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol 1989;11(3):303-307
8. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21(5):866-871
9. Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002;97(10):2670-2673
10. Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003;25(3):263-270
11. Kanda T, Yokosuka O, Hirasawa Y, et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology 2005;52(64):1233-1235
12. Maggiore G, Porta G, Bernard O, et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990;116(2):280-282
13. Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997;27(3): 578-582
14. Viruet EJ, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J 1998;17(3):297-300
15. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2(7):625-631
16. Miyake Y, Iwasaki Y, Terada R, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006;23(9):1347-1353
17. Ichai P, Duclos-Vallée J-C, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13(7): 996-1003
18. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002;35(1):75-81
19. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42(1):53-62
20. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009;29(6):816-823
21. Bittencourt PL, Farias AQ, Porta G, et al. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol 2008;42(3):300-305
22. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30(3):394-401
23. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc 1990; 65(1):23-30
24. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993; 104(6):1755-1761
25. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002;51(2):259-264
26. Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci 2007; 52(9):2433-2437
27. Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997;113(2):664-668
28. Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 2004;28(4):471-478
29. Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006;59(3):246-249
30. Miyake Y, Iwasaki Y, Terada R, et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res 2007;37(10):801-805
31. Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol 2007;38(11):1669-1675
32. Iwai M, Jo M, Ishii M, Mori T, Harada Y. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol Res 2008;38(8):784-789
33. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993;18(1):10-15
34. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31(6):1231-1238
35. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34(4 Pt 1):659-665
36. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004;24(4):322-329
37. Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 2001;96(12):3390-3394
38. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007;46(6):1828-1835
39. Flores YN, Yee HF Jr, Leng M, et al. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol 2008;103(9):2231-2238
40. Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology 2008;47(3):1058-1066
41. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008;6(4):379-388
42. Siegel AB, McBride RB, El-Serag HB, et al. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 2008;103(1):120-127
43. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97(8):2051-2057
44. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008;48(1):140-147
45. Lebovics E, Schaffner F, Klion FM, Simon C. Autoimmune chronic active hepatitis in postmenopausal women. Dig Dis Sci 1985;30(9):824-828
46. Wang KK, Czaja AJ. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis. Gastroenterology 1989;97(5):1288-1293
47. Schramm C, Kanzler S, zum Büschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001;96(5):1587-1591
48. Granito A, Muratori L, Pappas G, et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 2005;21(10):1273-1277
49. Verslype C, George C, Buchel E, Nevens F, van Steenbergen W, Fevery J. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005;21(6):695-699
50. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45(4):575-583
51. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43(3):532-538
52. Miyake T, Miyaoka H, Abe M, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006;36(2):139-142
53. Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 2008;25(3):219-239
54. Varma RR, Michelsohn NH, Borkowf HI, Lewis JD. Pregnancy in cirrhotic and noncirrhotic portal hypertension. Obstet Gynecol 1977;50(2):217-222
55. Steven MM, Buckley JD, Mackay IR. Pregnancy in chronic active hepatitis. Q J Med 1979;48(192):519-531
56. Heneghan MA, Norris SM, O'Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001;48(1):97-102
57. Buchel E, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002;97(12):3160-3165
58. Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin Arthritis Rheum 2005;35(1):49-56
59. Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101(3):556-560
60. de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006;101(6):1390-1392
61. Werner M, Björnsson E, Prytz H, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42(8):986-991
62. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008;7(3):319-333
63. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96(4):1224-1231
64. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002; 6(3):727-737
65. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006;43(2, Suppl 1): S132-S144
66. Lapierre P, Béland K, Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res 2007;149(3): 107-113
67. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 2007;1(1):113-128
68. Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008;14(21): 3306-3312
69. Czaja AJ. Progress in the diagnosis and treatment of autoimmune hepatitis. Minerva Med 2008;99(6):549-568
70. Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41(1):207-215
71. Newton JL, Burt AD, Park JB, Mathew J, Bassendine MF, James OFW. Autoimmune hepatitis in older patients. Age Ageing 1997;26(6):441-444
72. Parker DR, Kingham JG. Type 1 autoimmune hepatitis is primarily a disease of later life. QJM 1997;90:289-296
73. Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol 1995;19(6):699-708
74. Czaja AJ. Autoimmune liver disease and rheumatic manifestations. Curr Opin Rheumatol 2007;19(1):74-80
75. Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998;352(9121):26-29
76. Volta U, De Franceschi L, Molinaro N, et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998;43(10):2190-2195
77. Kaukinen K, Halme L, Collin P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002;122(4):881-888
78. Sedlack RE, Smyrk TC, Czaja AJ, Talwalkar JA. Celiac disease-associated autoimmune cholangitis. Am J Gastroenterol 2002;97(12):3196-3198
79. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004;2(2):107-112
80. Stevens FM, McLoughlin RM. Is coeliac disease a potentially treatable cause of liver failure? Eur J Gastroenterol Hepatol 2005;17(10):1015-1017
81. Caprai S, Vajro P, Ventura A, Sciveres M, Maggiore G; SIGENP Study Group for Autoimmune Liver Disorders in Celiac Disease. Autoimmune liver disease associated with celiac disease in childhood: a multicenter study. Clin Gastroenterol Hepatol 2008;6(7):803-806
82. Cosnes J, Cellier C, Viola S, et al; Groupe D'Etude et de Recherche Sur la Maladie Coeliaque. Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol 2008;6(7):753-758
83. Hall S, Czaja AJ, Kaufman DK, Markowitz H, Ginsburg WW. How lupoid is lupoid hepatitis? J Rheumatol 1986; 13(1):95-98
84. Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 2004; 63:123-129
85. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992;103(4):1290-1295
86. Homberg J-C, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;7(6):1333-1339
87. Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997;92(12):2197-2200
88. Bittencourt PL, Goldberg AC, Cançado ELR, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999;94(7): 1906-1913
89. Ma Y, Bogdanos DP, Hussain MJ, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006;130(3):868-882
90. Muratori P, Czaja AJ, Muratori L, et al. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci 2007;52(1):179-184
91. Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol 2006;45(6):844-850
92. Czaja AJ, Carpenter HA, Moore SB. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. Liver Int 2006; 26(5):552-558
93. Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol 2003; 37(4):315-329
94. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002;6(3):799-824
95. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis 2002;22(4):365-378
96. Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2007;4(4):202-214
97. Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol Dietol 2007;53(1):43-78
98. Luxon BA. Diagnosis and treatment of autoimmune hepatitis. Gastroenterol Clin North Am 2008;37(2):461-478, vii-viii
99. Larsen FS. Treatment of patients with severe autoimmune hepatitis. Minerva Gastroenterol Dietol 2008;54(1):57-63
100. Collier J. Bone disorders in chronic liver disease. Hepatology 2007;46(4):1271-1278
101. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988;8(4):781-784
102. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333(15):958-963
103. Wörns MA, Teufel A, Kanzler S, et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol 2008;103(1): 138-146
104. Cross TJS, Antoniades CG, Muiesan P, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007;13(10):1382-1388
105. De Paoli P, Battistin S, Santini GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol 1988;48(3):290-296
106. Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol 1992;22(11): 2989-2993
107. Murasko DM, Goonewardene IM. T-cell function in aging: mechanisms of decline. Annu Rev Gerontol Geriatr 1990; 10:71-96
108. Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity 1991;8(3):245-249
109. Currie MS. Immunosenescence. Compr Ther 1992;18(11): 26-34
110. Ben-Yehuda A, Weksler ME. Immune senescence: mechanisms and clinical implications. Cancer Invest 1992;10(6): 525-531
111. Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet 1968;2:24-26
112. Paganelli R, Quinti I, Fagiolo U, et al. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol 1992;90(2):351-354
113. Hooper B, Whittingham S, Mathews JD, Mackay IR, Curnow DH. Autoimmunity in a rural community. Clin Exp Immunol 1972;12(1):79-87
114. Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347(12):911-920
115. Vrieling H, Tates AD, Natarajan AT, van Zeeland AA. Age-related accumulation of mutations in human Tlymphocytes. Ann N Y Acad Sci 1992;663:36-42
116. Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci 1998;43(9):2149-2155
117. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33(1): 99-103
118. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008;43(10): 1232-1240
119. Rowley MJ, Mackay IR. Measurement of antibodyproducing capacity in man. I. The normal response to flagellin from Salmonella adelaide. Clin Exp Immunol 1969; 5(4):407-418
120. Eidinger D, Garrett TJ. Studies of the regulatory effects of the sex hormones on antibody formation and stem cell differentiation. J Exp Med 1972;136(5):1098-1116
121. Mackay IR, Wittingham S, Tait B. Genetic control of immune responsiveness in man. Vox Sang 1977;32(1):10-19
122. Lahita RG. The connective tissue diseases and the overall influence of gender. Int J Fertil Menopausal Stud 1996;41: 156-165
123. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science 1999;283(5406):1277-1278
124. McFarlane IG, Heneghan MA. Autoimmunity and the female liver. Hepatol Res 2004;28(4):171-176
125. Tong MJ, Hsieh J, Blatt LM. Demographics, treatment and a predictive model of survival in a population of chronic autoimmune hepatitis patients. Hepatology 1998; 28:549A
126. Heneghan MA, Kosar Y, McDougall NI, Portmann B, McFarlane IG, Harrison PM. Characteristics and outcome of a large male cohort with autoimmune hepatitis: prognostic indicator of treatment response and outcome. Gastroenterology 2000;118:A1009
127. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105(5):1502-1507
128. Czaja AJ, Strettell MDJ, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25(2):317-323
129. Paavonen T, Andersson LC, Adlercreutz H. Sex hormone regulation of in vitro immune response. Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures. J Exp Med 1981;154(6):1935-1945
130. Fox HS, Bond BL, Parslow TG. Estrogen regulates the IFN-g promoter. J Immunol 1991;146(12):4362-4367
131. Muller D, Chen M, Vikingsson A, Hildeman D, Pederson K. Oestrogen influences CD4+T-lymphocyte activity in vivo and in vitro in b 2-microglobulin-deficient mice. Immunology 1995;86(2):162-167
132. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25(3):541-547
133. Reber PM. Prolactin and immunomodulation. Am J Med 1993;95(6):637-644
134. Paavonen T. Hormonal regulation of immune responses. Ann Med 1994;26(4):255-258
135. Chao TC, Van Alten PJ, Greager JA, Walter RJ. Steroid sex hormones regulate the release of tumor necrosis factor by macrophages. Cell Immunol 1995;160(1):43-49
136. Kimura M, Tomita Y, Watanabe H, Sato S, Abo T. Androgen regulation of intra-and extra-thymic T cells and its effect on sex differences in the immune system. Int J Androl 1995;18(3):127-136
137. Nelson JL. Microchimerism: implications for autoimmune disease. Lupus 1999;8(5):370-374
138. Lambert NC, Evans PC, Hashizumi TL, et al. Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity. J Immunol 2000;164(11):5545-5548
139. Tanaka A, Lindor K, Ansari A, Gershwin ME. Fetal microchimerisms in the mother: immunologic implications. Liver Transpl 2000;6(2):138-143
140. Miozzo M, Selmi C, Gentilin B, et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 2007;46(2):456-462
141. Uribe M, Chavez-Tapia NC, Mendez-Sanchez N. Pregnancy and autoimmune hepatitis. Ann Hepatol 2006; 5(3):187-189
142. Willocx RG, Isselbacher KJ. Chronic liver disease in young people. Clinical features and course in thirty-three patients. Am J Med 1961;30:185-195
143. Read AE, Sherlock S, Harrison CV. Active "juvenile" cirrhosis considered as part of a systemic disease and the effect of corticosteroid therapy. Gut 1963;4:378-393
144. Nagy S, Bush MC, Berkowitz R, Fishbein TM, Gomez-Lobo V. Pregnancy outcome in liver transplant recipients. Obstet Gynecol 2003;102(1):121-128
145. Werner M, Björnsson E, Prytz H, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42(8):986-991
146. Rosenkrantz JG, Githens JH, Cox SM, Kellum DL. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol 1967;97(3):387-394
147. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40(158):159-185
148. Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63(5):820-833
149. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1(7806):735-737
150. Koretz RL, Lewin KJ, Higgins J, Fagen ND, Gitnick GL. Chronic active hepatitis. Who meets treatment criteria? Dig Dis Sci 1980;25(9):695-699
151. Hodges JR, Millward-Sadler GH, Wright R. Chronic active hepatitis: the spectrum of disease. Lancet 1982;1(8271): 550-552
152. De Groote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978;19(6): 510-513
153. Fevery J, Desmet VJ, DeGroote J. Long-term follow-up and management of asymptomatic chronic active hepatitis. In: Cohen S, Soloway RD, eds. Chronic Active Liver Disease. New York: Churchill Livingstone; 1983:51-64
154. Czaja AJ, Taswell HF, Rakela J, Schimek C. Frequency of antibody to hepatitis C virus in asymptomatic HBsAgnegative chronic active hepatitis. J Hepatol 1992;14(1):88-93
155. Czaja AJ, Magrin S, Fabiano C, et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci 1995;40(1):33-40
156. GeallMG, Schoenfield LJ, Summerskill WH. Classification and treatment of chronic active liver disease. Gastroenterology 1968;55:724-729
157. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC Jr; Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47(4):1363-1370
158. Lee TH, Kim WR, Benson JT, Therneau TM, Melton LJ III. Serum aminotransferase activity and mortality risk in a United States community. Hepatology 2008;47(3): 880-887
159. Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 1972;3(2):183-198
160. Schalm SW, Korman MG, Summerskill WHJ, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977;22(11):973-980
161. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981;304(1):5-9
162. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004;39(6):1631-1638
163. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40: 646-652
164. Porta G, Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Pediatr Gastroenterol Nutr 1990;11(1):138-140
165. Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF. Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. Mayo Clin Proc 1982;57(5):303-309
166. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988;95(2):448-453
167. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation [editorial]. Liver Transpl 2007;13(7): 953-955
168. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007;46(4):1138-1145
169. Czaja AJ. Current concepts in autoimmune hepatitis. Ann Hepatol 2005;4(1):6-24
170. Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gastroenterol Hepatol 2007;1(1):129-143
171. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13(5):490-495
172. Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol 1994;41(2):146-150
173. Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30(6):1374-1380
174. Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002;37(3):302-308
175. Goldberg AC, Bittencourt PL, Oliveira LC, et al. Autoimmune hepatitis in Brazil: an overview. Scand J Immunol 2007;66(2-3):208-216
176. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002;97(9): 2402-2407
177. Scott JD, Garland N. Chronic liver disease in Aboriginal North Americans. World J Gastroenterol 2008;14(29): 4607-4615
178. Minuk GY, Liu S, Kaita K, et al. Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can J Gastroenterol 2008;22(10):829-834
179. Chung HV, Riley M, Ho JK, et al. Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. Can J Gastroenterol 2007;21(9):565-568
180. Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002;50(5):713-717
181. D'Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 2005;25(2):325-330
182. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993;18(4):816-822
183. Czaja AJ, Santrach PJ, Breanndan Moore S. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001;46(1):140-147
184. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000;174:250-259
185. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002;47(10):2139-2150
186. Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002;6(3):707-725
187. Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002;22(4):353-364
188. Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991;337(8751):1183-1187
189. Huppertz HI, Treichel U, Gassel AM, Jeschke R, Meyer zum Büschenfelde K-H. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 1995;23(2):204-208
190. Tanaka H, Tujioka H, Ueda H, Hamagami H, Kida Y, Ichinose M. Autoimmune hepatitis triggered by acute hepatitis A. World J Gastroenterol 2005;11(38):6069-6071
191. Tabak F, Ozdemir F, Tabak O, Erer B, Tahan V, Ozaras R. Autoimmune hepatitis induced by the prolonged hepatitis A virus infection. Ann Hepatol 2008;7(2):177-179
192. Fainboim L, Cañero Velasco MC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001;33(6): 1512-1517
193. Tapia-Conyer R, Santos JI, Cavalcanti AM, et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 1999;61(5):825-829
194. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999;30(4):851-856
195. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999;117(3):645-652
196. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31:49-53
197. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002;35(1): 126-131
198. Hiraide A, Imazeki F, Yokosuka O, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol 2005;100(6):1322-1329
199. Fan L, Tu X, Zhu Y, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol 2005;20(2):249-255
200. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens 2007;69(3):227-235